viewCircassia Group PLC

Circassia Group agrees £5mln equity funding deal

Chairman Ian Johnson said he was “grateful” of the support from the company’s two key investors

Circassia Group PLC -
The company's Niox technology is used to help manage asthma

Circassia Group PLC (LON:CIR) said it has been provided access to a £5mln equity finance facility by the North Atlantic Small Companies Investment Trust (NASCIT) and noted stock market investor, Richard Griffiths.

The facility will be available until November 30, and the new stock will be issued at “the lower of 24.6p and the price at which Circassia may issue any other new ordinary shares”.

NASCIT will subscribe to 70% of the shares, Griffiths the remainder.

Chairman Ian Johnson said he was “grateful” of the support from the company’s two key investors.

While the return of the Tudorza and Duaklir assets to AstraZeneca has removed all debt from the Circassia balance sheet, the coronavirus pandemic had continued to impact the firm’s Niox business, he explained.

“In recent weeks sales figures do suggest a gradual improvement as lockdown restrictions are lifted in different geographical markets in which we operate,” Johnson went on.

“The timing and extent of this recovery remain, predictably, uncertain at the current time and accordingly, the Board believes that it is prudent to ensure the Company has access to additional liquidity should it be required in the coming months.

“I am grateful for the support of two of our largest shareholders during this period as we continue to restructure the company and invest in the Niox business to aid recovery and deliver long-term growth." 

Quick facts: Circassia Group PLC

Price: 31.6 GBX

Market: LSE
Market Cap: £119.13 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read